Literature DB >> 32114642

Profile of non-responder and late responder patients treated for diabetic macular edema: systemic and ocular factors.

Mariacristina Parravano1, Eliana Costanzo2, Giuseppe Querques3.   

Abstract

Diabetic macular edema (DME) treatment represents a challenge for the ophthalmologists, and several aspects of real treatment expectancy are still being discussed and not yet fully elucidated. A univocal definition of responsiveness to treatment has not been reached. How the clinicians can evaluate the therapeutic success? The evaluation of systemic and ocular factors should help in this complex management. The age influences the long-term outcomes, and the role of glycemic control is confounded by contrasting correlations between hemoglobin glycated A1c and DME. Long-term treatment success is influenced by baseline best-corrected visual acuity (BCVA), central macular thickness (CMT) and early BCVA response. Also baseline diabetic retinopathy severity scale score is useful to evaluate the chances of improvement before and during treatments. The time-switching was influenced by early BCVA response, however considering a delayed response in a percentage of patients. Several structural optical coherence tomography (OCT) findings could predict long-term success, as the presence of serous retinal detachment, hyperreflective retinal spots, the disruption of external limiting membrane and ellipsoid zone, the disorganization of inner retinal layers and continued increase in CMT were considered predictors of poor response to treatment. Foveal avascular zone enlargement, high number of microaneurysms (Mas), lower vessel density (VD) in deep capillary plexus and lower parafoveal VD in superficial capillary plexus were considered as OCT angiography biomarkers of poor responsiveness. The aim of this review is to report the factors that could influence the response to treatment of DME patients.

Entities:  

Keywords:  Diabetic macular edema; Late responder DME patients; Non-responder DME patients; Optical coherence tomography; Optical coherence tomography angiography

Mesh:

Substances:

Year:  2020        PMID: 32114642     DOI: 10.1007/s00592-020-01496-7

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  52 in total

Review 1.  Mechanisms of Retinal Fluid Accumulation and Blood-Retinal Barrier Breakdown.

Authors:  José Cunha-Vaz
Journal:  Dev Ophthalmol       Date:  2017-03-28

2.  Association of Abnormal Renal Profiles and Proliferative Diabetic Retinopathy and Diabetic Macular Edema in an Asian Population With Type 2 Diabetes.

Authors:  Yi-Ting Hsieh; Meng-Ju Tsai; Shih-Te Tu; Ming-Chia Hsieh
Journal:  JAMA Ophthalmol       Date:  2018-01-01       Impact factor: 7.389

3.  Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  David W Hutton; Joshua D Stein; Adam R Glassman; Neil M Bressler; Lee M Jampol; Jennifer K Sun
Journal:  JAMA Ophthalmol       Date:  2019-12-01       Impact factor: 7.389

4.  The Impact of Systemic Factors on Clinical Response to Ranibizumab for Diabetic Macular Edema.

Authors:  Rishi P Singh; Karishma Habbu; Justis P Ehlers; M Cecilia Lansang; Lauren Hill; Ivaylo Stoilov
Journal:  Ophthalmology       Date:  2016-05-24       Impact factor: 12.079

5.  Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

Authors:  Quan Dong Nguyen; David M Brown; Dennis M Marcus; David S Boyer; Sunil Patel; Leonard Feiner; Andrea Gibson; Judy Sy; Amy Chen Rundle; J Jill Hopkins; Roman G Rubio; Jason S Ehrlich
Journal:  Ophthalmology       Date:  2012-02-11       Impact factor: 12.079

6.  Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.

Authors:  David M Brown; Ursula Schmidt-Erfurth; Diana V Do; Frank G Holz; David S Boyer; Edoardo Midena; Jeffrey S Heier; Hiroko Terasaki; Peter K Kaiser; Dennis M Marcus; Quan D Nguyen; Glenn J Jaffe; Jason S Slakter; Christian Simader; Yuhwen Soo; Thomas Schmelter; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Oliver Zeitz; Carola Metzig; Jean-François Korobelnik
Journal:  Ophthalmology       Date:  2015-07-18       Impact factor: 12.079

7.  Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Neil M Bressler; Wesley T Beaulieu; Adam R Glassman; Kevin J Blinder; Susan B Bressler; Lee M Jampol; Michele Melia; John A Wells
Journal:  JAMA Ophthalmol       Date:  2018-03-01       Impact factor: 7.389

Review 8.  Novel therapeutic targets in diabetic macular edema: Beyond VEGF.

Authors:  Elizabeth A Urias; George A Urias; Finny Monickaraj; Paul McGuire; Arup Das
Journal:  Vision Res       Date:  2017-10-16       Impact factor: 1.886

9.  Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial.

Authors:  Neil H White; Wanjie Sun; Patricia A Cleary; Ronald P Danis; Matthew D Davis; Dean P Hainsworth; Larry D Hubbard; John M Lachin; David M Nathan
Journal:  Arch Ophthalmol       Date:  2008-12

10.  Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial.

Authors:  Susan B Bressler; Isoken Odia; Maureen G Maguire; Dilsher S Dhoot; Adam R Glassman; Lee M Jampol; Dennis M Marcus; Sharon D Solomon; Jennifer K Sun
Journal:  JAMA Ophthalmol       Date:  2019-04-01       Impact factor: 8.253

View more
  2 in total

1.  Aqueous Humor Analyses in Patients with Diabetic Retinopathy Who Had Undergone Panretinal Photocoagulation.

Authors:  Jin-Woo Kwon; Jusang Oh
Journal:  J Diabetes Res       Date:  2022-06-20       Impact factor: 4.061

2.  Optical Coherence Tomography Angiography Biomarkers Predict Anatomical Response to Bevacizumab in Diabetic Macular Edema.

Authors:  Ayman G Elnahry; Alia M Noureldine; Ahmed A Abdel-Kader; Osama A Sorour; David J Ramsey
Journal:  Diabetes Metab Syndr Obes       Date:  2022-02-09       Impact factor: 3.168

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.